SEC Stock Data Quick Answer Xenetic Biosciences, Inc. reported R&D Expense of $3.07 million for fiscal year 2025. Xenetic Biosciences, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $3.07M -6.8% 2024 $3.29M -5.9% 2023 $3.49M -26.7% 2022 $4.77M +50.8% 2021 $3.16M +82.7% 2020 $1.73M -64.6% 2019 $4.89M +69.5% 2018 $2.88M -29.0% 2017 $4.06M … Read more
Quick Answer Xenetic Biosciences, Inc. reported Stockholders Equity of $7.40 million for fiscal year 2025. Xenetic Biosciences, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $7.40M +23.1% 2024 $6.01M -38.7% 2023 $9.80M -28.2% 2022 $13.65M -25.8% 2021 $18.39M +50.6% 2020 $12.22M -29.0% 2019 $17.21M +73.6% 2018 $9.91M -30.7% 2017 $14.30M … Read more
Quick Answer Xenetic Biosciences, Inc. reported Long-Term Debt of $212.8 thousand for fiscal year 2013. Xenetic Biosciences, Inc. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2013 $212.8K +0.0% 2012 $212.8K +0.0% 2011 $212.8K — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ August 31, 2016 $212.8K — +0.0% May 31, … Read more
Quick Answer Xenetic Biosciences, Inc. reported Total Assets of $8.36 million for fiscal year 2025. Xenetic Biosciences, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $8.36M +21.2% 2024 $6.90M -34.9% 2023 $10.61M -28.0% 2022 $14.72M -25.7% 2021 $19.82M +50.3% 2020 $13.18M -38.8% 2019 $21.55M +49.3% 2018 $14.43M -24.7% 2017 $19.16M … Read more
Quick Answer Xenetic Biosciences, Inc. reported Diluted EPS of $1.58 per share (loss) for fiscal year 2025. Xenetic Biosciences, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$1.58 +38.5% 2024 -$2.57 +5.2% 2023 -$2.71 +41.2% 2022 -$4.61 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ September 30, 2025 … Read more
Quick Answer Xenetic Biosciences, Inc. reported Net Income of -$2.68 million for fiscal year 2025. Xenetic Biosciences, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$2.68M +32.3% 2024 -$3.96M +4.2% 2023 -$4.13M +36.9% 2022 -$6.55M -16.1% 2021 -$5.65M +48.2% 2020 -$10.89M +14.7% 2019 -$12.78M -75.0% 2018 -$7.30M -103.1% 2017 -$3.60M … Read more
Quick Answer Xenetic Biosciences, Inc. reported Total Revenue of $2.98 million for fiscal year 2025. Xenetic Biosciences, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $2.98M +19.0% 2024 $2.50M -1.6% 2023 $2.54M +48.8% 2022 $1.71M +47.1% 2021 $1.16M +165.6% 2020 $436.9K +2460.3% 2019 $17.1K — 2018 $0.00 -100.0% 2017 $7.58M … Read more
Quick Answer Xenetic Biosciences, Inc. reported Total Revenue of $2.98 million for fiscal year 2025. Xenetic Biosciences, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $2.98M+19.0% $2.50M-1.6% $2.54M+48.8% $1.71M+47.1% $1.16M+165.6% $436.9K+2460.3% Net Income -$2.68M+32.3% -$3.96M+4.2% -$4.13M+36.9% -$6.55M-16.1% -$5.65M+48.2% -$10.89M+14.7% Diluted EPS -$1.58+38.5% -$2.57+5.2% -$2.71+41.2% -$4.61 — — Total … Read more
Quick Answer Beyond Air, Inc. reported Shares Outstanding of 82.57 million shares for fiscal year 2025. Beyond Air, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 82.57M +79.9% 2024 45.90M +49.3% 2023 30.74M +2.9% 2022 29.89M +36.9% 2021 21.83M +35.9% 2020 16.06M +84.2% 2019 8.71M +3.8% 2018 8.40M +37.7% 2017 … Read more
Quick Answer Beyond Air, Inc. reported Gross Profit of -$1.66 million for fiscal year 2025. Beyond Air, Inc. Gross Profit — Annual History Fiscal Year Gross Profit YoY Change 2025 -$1.66M -27.2% 2024 -$1.31M -135.5% 2023 -$555.0K — Quarterly Gross Profit Quarter Ending Gross Profit YoY QoQ December 31, 2025 $300.0K +239.5% +200.7% September 30, … Read more